Gilman Hill Asset Management LLC Has $2.17 Million Stock Holdings in GSK plc (NYSE:GSK)

Gilman Hill Asset Management LLC lowered its stake in GSK plc (NYSE:GSK) by 4.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 64,262 shares of the pharmaceutical company’s stock after selling 3,160 shares during the period. Gilman Hill Asset Management LLC’s holdings in GSK were worth $2,173,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Eastern Bank bought a new position in shares of GSK during the third quarter worth approximately $26,000. Sunbelt Securities Inc. lifted its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners boosted its position in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares during the period. ST Germain D J Co. Inc. grew its stake in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares in the last quarter. Finally, Fortitude Family Office LLC acquired a new stake in GSK in the 3rd quarter worth about $42,000. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GSK shares. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Monday, January 13th. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.0 %

Shares of NYSE GSK opened at $33.46 on Monday. The stock has a 50-day moving average price of $34.02 and a two-hundred day moving average price of $37.98. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98. The company has a market cap of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a $0.3928 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 annualized dividend and a yield of 4.70%. GSK’s dividend payout ratio is presently 96.10%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.